A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00236613|
Recruitment Status : Completed
First Posted : October 12, 2005
Last Update Posted : December 3, 2010
|Condition or disease||Intervention/treatment||Phase|
|Obesity||Drug: topiramate||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||385 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity|
|Study Start Date :||September 2000|
|Study Completion Date :||July 2001|
- The percent change in body weight from baseline (at the time of randomization) to Week 24.
- Changes from baseline to week 24 in total body weight, body mass index, fasting plasma glucose; incidence of adverse events over study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00236613
|Study Director:||Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|